KS1/4-DAVLB, a monoclonal antibody-vinca alkaloid conjugate for site-directed therapy of epithelial malignancies.
Bumol
T F
TF
Lilly Research Laboratories, Indianapolis, Indiana.
Baker
A L
AL
Andrews
E L
EL
DeHerdt
S V
SV
Briggs
S L
SL
Spearman
M E
ME
Apelgren
L D
LD
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D051379:Mice; D008819:Mice, Nude; D009369:Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D014183:Transplantation, Heterologous; D014748:Vinca Alkaloids / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D000922:Immunotoxins; D014748:Vinca Alkaloids